



U.S. Application Serial No. 09/995,631
Attorney Docket No.: 38005-0158

AMENDMENTS


Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

Claims 1-36 (canceled).

Claim 37. (previously presented) A compound of the formula I



in which

W is R^1 -A-C(R^{13});

Y is a carbonyl, thiocarbonyl or methylene group;

Z is $N(R^0)$, oxygen, sulfur or a methylene group;

A is a bivalent radical selected from the group consisting of (C₁-C₆)-alkylene, (C₃-C₁₂)-cycloalkylene, (C₁-C₆)-alkylene-(C₃-C₁₂)-cycloalkyl, phenylene, phenylene-(C₁-C₆)-alkyl, (C₁-C₆)-alkylenephenyl, (C₁-C₆)-alkylenephenyl-(C₁-C₆)-alkyl, phenylene-(C₂-C₆)-alkenyl or a bivalent radical of a 5- or 6-membered saturated or unsaturated ring which can contain

1 or 2 nitrogen atoms and can be mono- or disubstituted by (C₁-C₆)-alkyl or doubly bonded oxygen or sulfur, or is a direct bond;

B is a bivalent radical selected from the group consisting of (C₁-C₆)-alkylene, (C₂-C₆)-alkenylene, phenylene, phenylene-(C₁-C₃)-alkyl, and (C₁-C₃)-alkylenephenoxy, where the bivalent (C₁-C₆)-alkylene radical can be unsubstituted or substituted by a radical from the group consisting of (C₁-C₈)-alkyl, (C₂-C₈)-alkenyl, (C₂-C₈)-alkynyl, (C₃-C₁₀)-cycloalkyl, (C₃-C₁₀)-cycloalkyl-(C₁-C₆)-alkyl, optionally substituted (C₆-C₁₄)-aryl, (C₆-C₁₄)-aryl-(C₁-C₆)-alkyl optionally substituted in the aryl radical, optionally substituted heteroaryl and heteroaryl-(C₁-C₆)-alkyl optionally substituted in the heteroaryl radical;

D is C(R²)(R³);

E is tetrazolyl, (R⁸O)₂P(O), HOS(O)₂, R⁹NHS(O)₂ or R¹⁰CO;


R is hydrogen, (C₁-C₈)-alkyl, (C₃-C₁₂)-cycloalkyl, (C₃-C₁₂)-cycloalkyl-(C₁-C₈)-alkyl, optionally substituted (C₆-C₁₄)-aryl, (C₆-C₁₄)-aryl-(C₁-C₈)-alkyl optionally substituted in the aryl radical, optionally substituted heteroaryl and heteroaryl-(C₁-C₈)-alkyl optionally substituted in the heteroaryl radical, where alkyl radicals can be mono- or polysubstituted by fluorine;

R⁰ is hydrogen, (C₁-C₈)-alkyl, (C₃-C₁₂)-cycloalkyl, (C₃-C₁₂)-cycloalkyl-(C₁-C₈)-alkyl, (C₆-C₁₂)-bicycloalkyl, (C₆-C₁₂)-bicycloalkyl-(C₁-C₈)-alkyl, (C₆-C₁₂)-tricycloalkyl, (C₆-C₁₂)-tricycloalkyl-(C₁-C₈)-alkyl, optionally substituted (C₆-C₁₄)-aryl, (C₆-C₁₄)-aryl-(C₁-C₈)-alkyl optionally substituted in the aryl radical, optionally substituted heteroaryl, heteroaryl-(C₁-C₈)-alkyl optionally substituted in the heteroaryl radical, CHO, (C₁-C₈)-alkyl-CO, (C₃-C₁₂)-

cycloalkyl-CO, (C₃-C₁₂)-cycloalkyl-(C₁-C₈)-alkyl-CO, (C₆-C₁₂)-bicycloalkyl-CO, (C₆-C₁₂)-bicycloalkyl-(C₁-C₈)-alkyl-CO, (C₆-C₁₂)-tricycloalkyl-CO, (C₆-C₁₂)-tricycloalkyl-(C₁-C₈)-alkyl-CO, optionally substituted (C₆-C₁₄)-aryl-CO, (C₆-C₁₄)-aryl-(C₁-C₈)-alkyl-CO optionally substituted in the aryl radical, optionally substituted heteroaryl-CO, heteroaryl-(C₁-C₈)-alkyl-CO optionally substituted in the heteroaryl radical, (C₁-C₈)-alkyl-S(O)_n, (C₃-C₁₂)-cycloalkyl-S(O)_n, (C₃-C₁₂)-cycloalkyl-(C₁-C₈)-alkyl-S(O)_n, (C₆-C₁₂)-bicycloalkyl-S(O)_n, (C₆-C₁₂)-bicycloalkyl-(C₁-C₈)-alkyl-S(O)_n, (C₆-C₁₂)-tricycloalkyl-S(O)_n, (C₆-C₁₂)-tricycloalkyl-(C₁-C₈)-alkyl-S(O)_n, optionally substituted (C₆-C₁₄)-aryl-S(O)_n, (C₆-C₁₄)-aryl-(C₁-C₈)-alkyl-S(O)_n optionally substituted in the aryl radical, optionally substituted heteroaryl-S(O)_n or heteroaryl-(C₁-C₈)-alkyl-S(O)_n optionally substituted in the heteroaryl radical, where n is 1 or 2;

R¹ is one of the radicals -S-R²¹, -S-S-R²¹, -S(O)-R²², -S(O)₂-R²², -S-OR²¹, -S(O)-OR²¹, -S(O)₂-OR²¹, -S-N(R²¹)-R²⁸, -S(O)-N(R²¹)-R²⁸, -S(O)₂-N(R²¹)-R²⁸, -S-C(O)-R²¹, -S-C(O)-OR²², -S-C(S)-SR²², -S-C(O)-N(R²¹)-R²⁸, -S-C(S)-N(R²¹)-R²⁸, -O-C(O)-R²¹, -O-C(S)-R²¹, -O-C(O)-OR²², -O-C(O)-N(R²¹)-R²⁸, -O-C(S)-N(R²¹)-R²⁸, -O-S(O)₂-OR²¹, -O-S(O)-OR²¹, -O-S(O)₂-N(R²¹)-R²⁸, -O-S(O)-N(R²¹)-R²⁸, -O-S(O)₂-R²², -O-S(O)-R²², -O-P(O)(OR²¹)₂, -O-P(O)(OR²¹)-N(R²¹)-R²⁸, -O-P(O)(N(R²¹)-R²⁸)₂, -N(R²⁹)-C(O)-OR²², -N(R²⁸)-C(O)-SR²², -N(R²⁸)-C(S)-OR²², -N(R²⁸)-C(S)-SR²², -N(R²⁸)-C(S)-R²¹, -N(R²⁸)-C(O)-N(R²¹)-R²⁸, -N(R²⁸)-C(S)-N(R²¹)-R²⁸, -N(R²⁸)-S(O)₂-R²², -N(R²⁸)-S(O)-R²², -N(R²⁸)-S(O)₂-OR²¹, -N(R²⁸)-S(O)-OR²¹, -N(R²⁸)-S(O)₂-N(R²¹)-R²⁸, -N(R²⁸)-S(O)-N(R²¹)-R²⁸, -N(R²⁸)-P(O)(OR²¹)₂, -N(R²⁸)-P(O)(OR²¹)-N(R²¹)-R²⁸, -N(R²⁸)-P(O)(N(R²¹)-R²⁸)₂, -N(R²⁸)-

$P(O)(R^{22})$ -OR²¹, -N(R²⁸)-P(O)(R²²)-N(R²¹)-R²⁸, -N(R²⁸)-P(O)(R²²)₂, P(O)(OR²¹)₂,
-P(O)(OR²¹)-N(R²¹)-R²⁸, -P(O)(N(R²¹)-R²⁸)₂, -P(O)(R²²)-OR²¹, -P(O)(R²²)-N(R²¹)-R²⁸,
-P(O)(R²²)₂, C(S)-R²¹, -C(S)-SR²¹, C(S)-N(R²¹)-R²⁸, cyano, halogen, nitro or
methylenedioxy or the radical of an optionally substituted, 5- to 14-membered, mono- or
polycyclic, saturated or unsaturated heterocyclic ring of the formula



in which

Q^1 is $-C(R^{21})_2-$, $=C(R^{21})-$, $-N(R^{28})-$, $-O-$ or $-S-$;

Q^2 is $S(O)-$ or $S(O)_2-$;

Q^3 is $-C(R^{21})_2-$, $=C(R^{21})-$, $-N(R^{28})-$, $-O-$, $-S-$, $-C(R^{21})(-)$ or $-N(-)$, where the heterocyclic ring is
optionally bonded to the group A via the free bond in the groups $-C(R^{21})(-)$ or $-N(-)$
representing Q^3 or via any other desired ring carbon atom and where, if the heterocyclic ring
is bonded to a ring system contained in the group A, the heterocyclic ring can also be fused
via two adjacent atoms to the ring system in the group A;

R^2 is hydrogen, (C₁-C₈)-alkyl, optionally substituted (C₆-C₁₄)-aryl, (C₆-C₁₄)-aryl-(C₁ alkyl
optionally substituted in the aryl radical or (C₃-C₈)-cycloalkyl;

R^3 is (C₂-C₈)-alkenylcarbonyl, (C₂-C₈)-alkynylcarbonyl, R⁴CO, COOR⁴, CON(CH₃)R⁴,
CONHR⁴, or CSNHR⁴;

R^4 is hydrogen or (C_1 - C_{28})-alkyl which can optionally be mono- or polysubstituted by identical or different radicals selected from the group consisting of hydroxyl, hydroxycarbonyl, aminocarbonyl, mono- or di-((C_1 - C_{18})-alkyl)aminocarbonyl, amino- $(C_2$ - C_{18})-alkylaminocarbonyl, amino- $(C_1$ - C_3)-alkylphenyl- $(C_1$ - C_3)-alkylaminocarbonyl, (C_1 - C_{18})-alkylcarbonylamino- $(C_1$ - C_3)-alkylphenyl- $(C_1$ - C_3)-alkylaminocarbonyl, (C_1 - C_{18})-alkylcarbonyl amino- $(C_2$ - C_{18})-alkylaminocarbonyl, (C_6 - C_{14})-aryl- $(C_1$ - C_8)-alkoxycarbonyl optionally substituted in the aryl radical, amino, mercapto, (C_1 - C_{18})-alkoxy, (C_1 - C_{18})-alkoxycarbonyl, Het-CO, optionally substituted (C_3 - C_8)-cycloalkyl, $HOS(O)_2$ - $(C_1$ - C_3)-alkyl, $R^9NHS(O)_2$ - $(C_1$ - C_3)-alkyl, $(R^8O)_2P(O)$ - $(C_1$ - C_3)-alkyl, tetrazolyl- $(C_1$ - C_3)-alkyl, halogen, nitro, trifluoromethyl or the radical R^5 ;

R^5 is optionally substituted (C_6 - C_{14})-aryl, (C_6 - C_{14})-aryl- $(C_1$ - C_8)-alkyl optionally substituted in the aryl radical, a mono- or bicyclic 5- to 12-membered heterocyclic ring which can be aromatic, partially hydrogenated or completely hydrogenated and which can contain one, two or three identical or different heteroatoms from the group consisting of nitrogen, oxygen and sulfur, a radical R^6 or a radical R^6CO , where the aryl radical and, independently thereof, the heterocyclic radical can be mono- or polysubstituted by identical or different radicals from the group consisting of (C_1 - C_{18})-alkyl, (C_1 - C_{18})-alkoxy, halogen, nitro, amino and trifluoromethyl;

R^6 is R^7R^8N , R^7O or R^7S or an amino acid side chain, a natural or unnatural amino acid, imino acid, optionally N- $(C_1$ - C_8)-alkylated or N-((C_6 - C_{14})-aryl- $(C_1$ - C_8)-alkylated) aza-amino acid or a dipeptide radical wherein the aryl group of the aza-amino acid is optionally substituted

and/or in which the peptide bond can be reduced to -NH-CH₂-, esters and amides thereof, wherein hydrogen or hydroxymethyl can optionally stand in place of free functional groups and/or where free functional groups can be protected by protective groups customary in peptide chemistry;

R⁷ is hydrogen, (C₁-C₁₈)-alkyl, (C₆-C₁₄)-aryl-(C₁-C₈)-alkyl, (C₁-C₁₈)-alkylcarbonyl, (C₁-C₁₈)-alkoxycarbonyl, (C₆-C₁₄)-arylcarbonyl, (C₆-C₁₄)-aryl-(C₁-C₈)-alkylcarbonyl or (C₆-C₁₄)-aryl-(C₁-C₁₈)-alkyloxycarbonyl, where the alkyl groups are optionally substituted by an amino group and/or where the aryl radicals can be mono- or polysubstituted by identical or different radicals selected from the group consisting of (C₁-C₁₈)-alkyl, (C₁-C₈)-alkoxy, halogen, nitro, amino and trifluoromethyl, or R⁷ is a natural or unnatural amino acid, imino acid, optionally N-(C₁-C₈)-alkylated or N-((C₆-C₁₄)-aryl-(C₁-C₈)-alkylated) aza-amino acid or a dipeptide radical wherein the aryl group of the aza-amino acid is optionally substituted and/or in which the peptide bond can be reduced to -NH-CH₂;

R⁸ is hydrogen, (C₁-C₈)-alkyl, optionally substituted (C₆-C₁₄)-aryl or (C₆-C₁₄)-aryl-(C₁-C₈)-alkyl optionally substituted in the aryl radical;

R⁹ is hydrogen, aminocarbonyl, (C₁-C₁₈)-alkylaminocarbonyl, (C₃-C₈)-cycloalkylaminocarbonyl, optionally substituted (C₆-C₁₄)-arylaminocarbonyl, (C₁-C₁₈)-alkyl, optionally substituted (C₆-C₁₄)-aryl or (C₃-C₈)-cycloalkyl;

R¹⁰ is hydroxyl, (C₁-C₁₈)-alkoxy, (C₆-C₁₄)-aryl-(C₁-C₈)-alkoxy optionally substituted in the aryl radical, optionally substituted (C₆-C₁₄)-aryloxy, amino or mono- or di-((C₁-C₁₈)-alkyl)amino;

R^{13} is hydrogen, (C_1-C_6) -alkyl, optionally substituted (C_6-C_{14}) -aryl, (C_6-C_{14}) -aryl- (C_1-C_8) -alkyl optionally substituted in the aryl radical, (C_3-C_8) -cycloalkyl or (C_3-C_8) -cycloalkyl- (C_1-C_8) -alkyl;

R^{21} is hydrogen, (C_1-C_8) -alkyl, hydroxy- (C_1-C_8) -alkyl, (C_2-C_8) -alkenyl, (C_3-C_{12}) -cycloalkyl, (C_3-C_{12}) -cycloalkyl- (C_1-C_8) -alkyl, optionally substituted (C_6-C_{14}) -aryl, (C_6-C_{14}) -aryl- (C_1-C_8) -alkyl optionally substituted in the aryl radical, optionally substituted heteroaryl or heteroaryl- (C_1-C_8) -alkyl optionally substituted in the heteroaryl radical, where alkyl radicals optionally monosubstituted or polysubstituted by fluorine and the radicals R^{21} can be identical or different if they occur two or more times;

R^{22} is (C_1-C_8) -alkyl, hydroxy- (C_1-C_8) -alkyl, (C_2-C_8) -alkenyl, (C_3-C_{12}) -cycloalkyl, (C_3-C_{12}) -cycloalkyl- (C_1-C_8) -alkyl, optionally substituted (C_6-C_{14}) -aryl, (C_6-C_{14}) -aryl- (C_1-C_8) -alkyl optionally substituted in the aryl radical, optionally substituted heteroaryl or heteroaryl- (C_1-C_8) -alkyl optionally substituted in the heteroaryl radical, where alkyl radicals can be monosubstituted or polysubstituted by fluorine and the radicals R^{22} can be identical or different if they occur two or more times;

R^{28} is one of the radicals $R^{21}-$, $R^{21}N(R^{21})-$, $R^{21}C(O)-$, $R^{22}O-C(O)-$, $R^{21}N(R^{21})-C(O)-$ or $R^{21}N(R^{21})-C(=N(R^{21}))-$;

R^{29} is one of the radicals $R^{22}-$, $R^{21}N(R^{21})-$, $R^{21}C(O)-$, $R^{22}O-C(O)-$, $R^{21}N(R^{21})-C(O)-$ or $R^{21}N(R^{21})-C(=N(R^{21}))-$;

Het is the radical of a 5- to 10-membered, monocyclic or polycyclic heterocycle bonded via a nitrogen atom, which can be aromatic or partially unsaturated or saturated and which can

contain one, two, three or four identical or different additional ring heteroatoms from the group consisting of oxygen, nitrogen and sulfur and which can be optionally substituted on carbon atoms and on additional ring nitrogen atoms, where there can be identical or different radicals R^h , R^hCO or R^hO-CO as substituents on additional ring nitrogen atoms and R^h is hydrogen, (C₁-C₈)-alkyl, (C₃-C₈)-cycloalkyl, (C₃-C₈)-cycloalkyl-(C₁-C₈)-alkyl, optionally substituted (C₆-C₁₄)-aryl or (C₆-C₁₄)-aryl-(C₁-C₈)-alkyl optionally substituted in the aryl radical;

b, c, and d are 1, e and f are 0; and

g and h independently of one another are 0, 1, 2, 3, 4, 5 or 6;

or a stereoisomer thereof, or a physiologically tolerable salt thereof.

Claim 38. (previously presented) A compound of the formula I as claimed in claim 37, in which

B is a bivalent radical selected from the group consisting of (C₁-C₆)-alkylene, (C₂-C₆)-alkenylene, phenylene, phenylene-(C₁-C₃)-alkyl, and (C₁-C₃)-alkylenephenyl;
R and R⁰ independently of one another are hydrogen, (C₁-C₈)-alkyl, (C₃-C₁₂)-cycloalkyl, (C₃-C₁₂)-cycloalkyl-(C₁-C₈)-alkyl, optionally substituted (C₆-C₁₄)-aryl, (C₆-C₁₄)-aryl-(C₁-C₈)-alkyl optionally substituted in the aryl radical, optionally substituted heteroaryl or heteroaryl-(C₁-C₈)-alkyl optionally substituted in the heteroaryl radical, where alkyl radicals can be mono- or polysubstituted by fluorine;


R^4 is hydrogen or (C_1 - C_{28})-alkyl which can optionally be mono- or polysubstituted by identical or different radicals selected from the group consisting of hydroxyl, hydroxycarbonyl, aminocarbonyl, mono- or di-((C_1 - C_8)-alkyl)aminocarbonyl, amino- $(C_2$ - C_{18})-alkyl-aminocarbonyl, amino- $(C_1$ - C_3)-alkylphenyl- $(C_1$ - C_3)-alkylaminocarbonyl, (C_1 - C_8)-alkylcarbonylamino- $(C_1$ - C_3)-alkylphenyl- $(C_1$ - C_3)-alkylaminocarbonyl, (C_1 - C_{18})-alkylcarbonylamino- $(C_2$ - C_{18})-alkylaminocarbonyl, (C_6 - C_{14})-aryl- $(C_1$ - C_8 alkoxycarbonyl optionally substituted in the aryl radical, amino, mercapto, (C_1 - C_{18})-alkoxy, (C_1 - C_{18})-alkoxycarbonyl, optionally substituted (C_3 - C_8)-cycloalkyl, $HOS(O)_2$ - $(C_1$ - C_3)-alkyl, $R^9NHS(O)_2$ - $(C_1$ - C_3)-alkyl, $(R^8O)_2P(O)$ - $(C_1$ - C_3)-alkyl, tetrazolyl- $(C_1$ - C_3)-alkyl, halogen, nitro, trifluoromethyl or the radical R^5 ;

R^{13} is hydrogen, (C_1 - C_6)-alkyl, (C_6 - C_{14})-aryl- $(C_1$ - C_8)-alkyl optionally substituted in the aryl radical or (C_3 - C_8)-cycloalkyl;

or a stereoisomer thereof, or a physiologically tolerable salt thereof.

Claim 39. (previously presented) A compound of the formula I as claimed in claim 37, in which R^1 is one of the radicals $-S(O)-N(R^{21})-R^{28}$, $-S(O)_2-N(R^{21})-R^{28}$, $O-C(O)-R^{21}$, $-O-C(O)-OR^{22}$, $-O-C(O)-N(R^{21})-R^{28}$, $-O-C(S)-N(R^{12})-R^{28}$, $-O-S(O)_2-N(R^{21})-R^{28}$, $-O-S(O)-N(R^{21})-R^{28}$, $-N(R^{29})-C(O)-OR^{22}-N(R^{28})-C(S)-R^{21}$, $-N(R^{28})-C(O)-N(R^{21})-R^{28}$, $-N(R^{28})-C(S)-N(R^{21})-R^{28}$, $-N(R^{28})-S(O)_2-R^{22}$, $-N(R^{28})-S(O)-R^{22}$, $-N(R^{28})-S(O)_2-OR^{21}$, $-N(R^{28})-S(O)-OR^{21}$, $-N(R^{28})-S(O)_2-N(R^{21})-R^{28}$, $-N(R^{28})-S(O)-N(R^{21})-R^{28}$, $-C(S)-R^{21}$, $-C(S)-N(R^{21})-R^{28}$ or cyano or the radical of an optionally

substituted, 5- to 14-membered, mono- or polycyclic, saturated or unsaturated heterocyclic ring of the formula



in which

Q^1 is $-C(R^{21})_2-$, $=C(R^{21})-$, $-N(R^{28})-$, $-O-$ or $-S-$;

Q^2 is $-S(O)-$ or $-S(O)_2-$;

Q^3 is $-C(R^{21})_2-$, $=C(R^{21})-$, $-N(R^{28})-$, $-O-$, $-S-$, $-C(R^{21})(-)-$ or $-N(-)-$, where the heterocyclic is optionally bonded to the group A via the free bond in the groups $-C-(R^{21})(-)-$ or $-N(-)-$ representing Q^3 or via any other desired ring carbon atom and where, if the heterocyclic ring is bonded to a ring system contained in the group A, the heterocyclic ring can also be fused via two adjacent atoms to the ring system in the group A; or a stereoisomer thereof, or a physiologically tolerable salt thereof.

Claim 40. (previously presented) A compound of the formula I as claimed in claim 37, in which R^0 is (C_1-C_8) -alkyl, (C_3-C_{12}) -cycloalkyl, (C_3-C_{12}) -cycloalkyl- (C_1-C_8) -alkyl, optionally substituted (C_6-C_{14}) -aryl, (C_6-C_{14}) -aryl- (C_1-C_8) -alkyl optionally substituted in the aryl radical, optionally substituted heteroaryl or heteroaryl- (C_1-C_8) -alkyl optionally substituted in the heteroaryl radical; or a stereoisomer thereof, or a physiologically tolerable salt thereof.

Claim 41. (previously presented) A compound of the formula I as claimed in claim 40, wherein R⁰ is selected from the group consisting of biphenylylmethyl, naphthylmethyl, and benzyl, each of which is unsubstituted or monosubstituted or polysubstituted in the aryl radical; or a stereoisomer thereof, or a physiologically tolerable salt thereof.

Claim 42. (previously presented) A compound of the formula I as claimed in claim 37, in which

A is a bivalent radical from the group consisting of methylene, ethylene, trimethylene, tetramethylene, pentamethylene, cyclohexylene, phenylene, phenylenemethyl, methylenephenoxy, methylenephenylmethyl;

B is a bivalent radical selected from the group consisting of methylene, ethylene, trimethylene, tetramethylene, vinylene, phenylene, or substituted methylene or ethylene;


E is R¹⁰CO;

R is hydrogen, (C₁-C₆)-alkyl or benzyl;

R⁰ is (C₁-C₈)-alkyl (C₃-C₈)-cycloalkyl, optionally substituted (C₆-C₁₄)-aryl or (C₆-C₁₄)-aryl-(C₁-C₈)-alkyl optionally substituted in the aryl radical;

R¹ is one of the radicals -S(O)-N(R²¹)-R²⁸, -S(O)₂-N(R²¹)-R²⁸, -O-C(O)-R²¹, -O-C(O)-OR²², -O-C(O)-N(R²¹)-R²⁸, -O-C(S)-N(R²¹)-R²⁸, -O-S(O)₂-N(R²¹)-R²⁸, -O-S(O)-N(R²¹)-R²⁸, -N(R²⁹)-C(O)-OR²², -N(R²⁸)-C(S)-R²¹, -N(R²⁸)-C(O)-N(R²¹)-R²⁸, -N(R²⁸)-C(S)-N(R²¹)-R²⁸, -N(R²⁸)-S(O)₂-R²², -N(R²⁸)-S(O)-R²², -N(R²⁸)-S(O)₂-OR²¹, -N(R²⁸)-S(O)-OR²¹, -N(R²⁸)-S(O)₂-N(R²¹)-R²⁸, -N(R²⁸)-S(O)-N(R²¹)-R²⁸, -C(S)-R²¹, -C(S)-N(R²¹)-R²⁸ or cyano or the

radical of an optionally substituted, 5- to 14-membered, mono- or polycyclic, saturated or unsaturated heterocyclic ring of the formula



in which

Q^1 is $-C(R^{21})_2-$, $=C(R^{21})-$, $-N(R^{28})-$, $-O-$ or $-S-$;

Q^2 is $-S(O)-$ or $-S(O)_2-$;

Q^3 is $-C(R^{21})_2-$, $=C(R^{21})-$, $-N(R^{28})-$, $-O-$, $-S-$, $-C(R^{21})(-)-$ or $-N(-)-$, where the heterocyclic ring can be bonded to the group A via the free bond in the groups $-C(R^{21})(-)-$ or $-N(-)-$ representing Q^3 or via any other desired ring carbon atom and where, if the heterocyclic ring is bonded to a ring system contained in the group A, the heterocyclic ring can also be fused via two adjacent atoms to the ring system in the group A;

R^2 is hydrogen or (C_1-C_8) -alkyl.

R^3 is R^4CO , $COOR^4$, $CONHR^4$, or $CSNHR^4$;

and g and h independently of one another are the numbers 0, 1, 2 or 3;

or a stereoisomer thereof, or a physiologically tolerable salt thereof.

Claim 43. (previously presented) A compound of the formula I as claimed in claim 37, in which R¹³ is (C₁-C₆)-alkyl, (C₆-C₁₄)-aryl-(C₁-C₈)-alkyl optionally substituted in the aryl radical or (C₃-C₈)-cycloalkyl; or a stereoisomer thereof, or a physiologically tolerable salt thereof.

Claim 44. (currently amended): [[A]] The compound of the formula I as claimed in claim 37, ~~in which~~ wherein R³ is COOR⁴[[,]] or CONHR⁴, and wherein [[CO]]-NHR⁴ is the radical of an α -amino acid, an ω -amino-(C₂-C₈)-alkylamide thereof, its (C₁-C₈)-alkyl ester, its (C₆-C₁₄)-aryl-(C₁-C₄)-alkyl ester, or its derivative in which the carboxylic acid group is converted into the group Het-CO, or a stereoisomer thereof, or a physiologically tolerable salt thereof.

Claim 45. (currently amended): [[A]] The compound of the formula I as claimed in claim 44, wherein the radical of the α -amino acid is selected from the group consisting of valine, lysine, phenylglycine, phenylalanine, tryptophan, (C₁-C₈)-alkyl esters, (C₆-C₄)-aryl-(C₁-C₄)-alkyl esters, and Het-CO derivatives thereof; or a stereoisomer thereof, or a physiologically tolerable salt thereof.

Claim 46. (previously presented) A compound of the formula I as claimed in claimed 37, in which simultaneously

Y is a carbonyl group;

Z is N(R⁰);

A is ethylene, trimethylene, tetramethylene, pentamethylene, cyclohexylene, phenylene, phenylenemethyl, methylenephenoxy or methylenephenoxyethyl;

B is an unsubstituted or substituted methylene radical;

E is $R^{10}CO$;

R is hydrogen or (C_1-C_4) -alkyl;

R^0 is (C_1-C_8) -alkyl, (C_3-C_8) -cycloalkyl, optionally substituted (C_6-C_{14}) -aryl or (C_6-C_{14}) -aryl- (C_1-C_8) -alkyl optionally substituted in the aryl radical;

R^1 is one of the radicals $-O-C(O)-R^{21}$, $-O-C(O)-OR^{22}$, $-O-C(O)-N(R^{21})-R^{28}$, $-N(R^{29})-C(O)-OR^{22}$, $-N(R^{28})-C(O)-N(R^{21})-R^{28}$, $-N(R^{28})-C(S)-N(R^{21})-R^{28}$ or cyano;

R^2 is hydrogen;

R^3 is the radical $CONHR^4$;

R^4 is methyl which is substituted by hydroxycarbonyl and a radical from the group consisting of (C_1-C_4) -alkyl, phenyl and benzyl, or is methyl which is substituted by (C_1-C_8) -alkoxycarbonyl and a radical from the group consisting of (C_1-C_4) -alkyl, phenyl and benzyl, or is methyl which is substituted by Het-CO and a radical from the group consisting of (C_1-C_4) -alkyl, phenyl and benzyl;

R^{10} is hydroxyl or (C_1-C_8) -alkoxy;

R^{13} is (C_1-C_6) -alkyl, (C_3-C_7) -cycloalkyl or benzyl;

e, f and g are 0; and

h is 1 or 2;

or a stereoisomer thereof, or a physiologically tolerable salt thereof.

Claim 47. (previously presented) A compound of the formula I as claimed in claim 37, in which a substituted methylene radical or substituted ethylene radical representing the group B carries as a substituent a radical from the group consisting of (C₁-C₈)-alkyl, (C₂-C₆)-alkenyl, (C₂-C₆)-alkynyl and (C₃-C₈)-cycloalkyl, (C₃-C₈)-cycloalkyl-(C₁-C₄)-alkyl, optionally substituted (C₆-C₁₀)-aryl, (C₆-C₁₀)-aryl-(C₁-C₄)-alkyl optionally substituted in the aryl radical, optionally substituted heteroaryl, and heteroaryl-(C₁-C₄)-alkyl optionally substituted in the heteroaryl radical, or a stereoisomer thereof, or a physiologically tolerable salt thereof.

Claim 48. (previously presented) A compound of the formula I as claimed in claim 37, in which B is an unsubstituted methylene radical or a methylene radical which is substituted by a (C₁-C₈)-alkyl radical; or a stereoisomer thereof, or a physiologically tolerable salt thereof.

Claim 49. (previously presented) A compound of the formula I as claimed in claim 37, in which R¹ is one of the radicals -O-C(O)-R²¹, -O-C(O)-OR²², -O-C(O)-N(R²¹)-R²⁸, -N(R²⁹)-C(O)-OR²², -N(R²⁸)-C(O)-N(R²¹)-R²⁸, -N(R²⁸)-C(S)-N(R²¹)-R²⁸ or cyano; or a stereoisomer thereof, or a physiologically tolerable salt thereof.

Claim 50. (canceled).

Claim 51. (currently amended): A **pharmaceutical** preparation comprising one or more of the compounds of the formula I as claimed in claim 37 or a stereoisomer thereof, or a physiologically tolerable salt thereof; and one or more pharmaceutically innocuous carriers and/or additives.

Claim 52. (previously presented) A kit comprising a VLA-4-antagonizing effective amount of one or more compounds of the formula I as claimed in claim 37 or a stereoisomer thereof, or a physiologically tolerable salt thereof; instructions for use; and one or more pharmaceutically innocuous carriers and/or additives.

Claim 53. (previously presented) A method for inhibiting adhesion of leukocytes to endothelial cells in a mammal, comprising administering to a subject in need thereof a VLA-4 antagonizing amount of a compound according to claim 37 for a time sufficient to antagonize VLA-4.

Claims 54-57. (canceled).